Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma
Clinical trial NCT05320081 · UNKNOWN
Trial details
- NCT number
- NCT05320081
- Sponsor
- Huazhong University of Science and Technology
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-30
- Primary completion
- 2023-12-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.